Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants - Takashita, Emi; Yamayoshi, Seiya; Simon, Viviana; van Bakel, Harm; Sordillo, Emilia M.; Pekosz, Andrew; Fukushi, Shuetsu; Suzuki, Tadaki; Maeda, Ken; Halfmann, Peter; Sakai-Tagawa, Yuko; Ito, Mutsumi; et al. (The New England journal of medicine, 2022)
Keywords: Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - immunology; Antiviral agents; Antiviral Agents - therapeutic use; Coronavirus; Coronaviruses; Correspondence; COVID-19; COVID-19 - immunology; COVID-19 Drug Treatment; Disease transmission; Drugs; FDA approval; Humans; Immunologic Factors - therapeutic use; Infectious Disease; Infectious diseases; Influenza; Monoclonal antibodies; Mutation; Pathogenesis; Proteins; R&D; Research & development; RNA polymerase; SARS-CoV-2 - drug effects; Severe acute respiratory syndrome coronavirus 2; Vaccine Efficacy; Viral Infections; United States--US; Japan